This is a routine corporate philanthropy press release with zero trading implications. No action required, ignore for investment purposes.
REGN drugs
REGN drug pipeline →- ● Otarmeni 3/10 Approved (accelerated approval) · BLA filing 2026
- ▲ Cemdisiran 6/10 Filed/PDUFA (Phase 3 NIMBLE complete; NDA under FDA Priority Review)
- ▲ Dupixent 4/10 Approved (marketed since 2017; additional Phase 3 trials ongoing for label expansion)
- ● Evkeeza 4/10 Approved
- ● EYLEA HD 4/10 Approved
- 12 more · All REGN drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 15 $696.20entry
- T+1 · 6mo ago −9.60%α −9.54% · $629.34
- T+5 · 6mo ago −8.28%α −9.25% · $638.53
- T+20 · 5mo ago −11.67%α −13.78% · $614.98
- T+60 · 3mo ago +14.46%α +10.21% · $796.84
Price Chart
How similar events traded
Executive Summary
Regeneron announced the winners of its 2026 International Science and Engineering Fair (ISEF), awarding over $7 million in prizes to high school students. This is a philanthropic/PR event with no direct financial impact on Regeneron's business or stock.
Key Facts
- Regeneron ISEF 2026 awarded over $7 million in prizes to more than 1,700 finalists from 67+ countries
- Top prize: $100,000 George D. Yancopoulos Innovator Award to Hikaru Kuribayashi for origami-folding simulation software
- Regeneron's total support for ISEF and Science Talent Search will exceed $300 million from 2017 to 2036
- No financial results, guidance, or business developments disclosed
Financial Impact
No revenue or earnings impact; $300M total sponsorship commitment through 2036 is a pre-existing, non-material expense for a $74.7B market cap company
Risk Factors
- None from this filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3296082 |
Track record
53 reports on REGN
11 of 17 bullish or bearish reports moved the stock their way by T+20. Best: +31.76% at T+20 after the Oct 6, 2026 report. 17 of 21 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $951.23 Now $952.40 +0.12% settles Dec 16
- Nov 16, 2026today 144 Neutral 2/10 Entry $948.00 Now $952.40 +0.46% settles Dec 16
- Nov 12, 20264d ago Press Release Bullish 5/10 Entry $955.47 Now $952.40 −0.32% settles Dec 14
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 5, 202611d ago Insider Cluster Neutral 3/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 4, 202612d ago 144 Neutral 1/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers